Meeting
2018 ASCO Annual Meeting
PD-L1 genomic alterations (GA) in solid tumors and hematologic malignancies: A comprehensive genomic profiling (CGP) study.
Authors
Laurie M. Gay
Foundation Medicine, Inc., Cambridge, MA
Laurie M. Gay , David Fabrizio , Garrett Michael Frampton , Lee A. Albacker , Ethan Sokol , Julia Andrea Elvin , Jo-Anne Vergilio , James Suh , Shakti H. Ramkissoon , Eric Allan Severson , Sugganth Daniel , Siraj Mahamed Ali , Jon Chung , Alexa Betzig Schrock , Vincent A. Miller , Jeffrey J. Pu , Robert John Corona , Gennady Bratslavsky , Jeffrey S. Ross
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Tumor Biology
Track
Tumor Biology
Sub Track
Tumor-Based Biomarkers
Citation
J Clin Oncol 36, 2018 (suppl; abstr 12092)
DOI
10.1200/JCO.2018.36.15_suppl.12092
Abstract #
12092
Poster Bd #
205
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
Impact of PD-L1 expression on conventional urothelial bladder carcinoma (UBC) genomic alteration (GA) profile.
First Author: Petros Grivas
Poster
2022 ASCO Annual Meeting
Landscape analysis of urothelial carcinoma (UC) by telomerase reverse transcriptase (TERT) alterations.
First Author: Tyler F. Stewart
Poster
2024 ASCO Annual Meeting
Genomic characteristics of exceptional responders to treatment with PD-1 inhibitors in refractory/metastatic head and neck squamous cell carcinoma.
First Author: Mark Chang
Poster
2022 ASCO Annual Meeting
Genomic correlates of acquired resistance to PD-(L)1 blockade in patients with advanced non-small cell lung cancer (NSCLC).
First Author: Biagio Ricciuti